Cancerous inhibitor of protein phosphatase 2A enhances chemoresistance of gastric cancer cells to oxaliplatin

Figure 2 High expression of cancerous inhibitor of protein phosphatase 2A was associated with poor overall survival rate and progression-free survival rate in patients with gastric cancer. A: Based on the Kaplan–Meier analysis, a high cancerous inhibitor of protein phosphatase 2A (CIP2A) expression was associated with overall survival (P = 0.0375) in 108 patients with gastric cancer; B: Based on the Kaplan–Meier analysis, a high CIP2A expression was associated with progression-free survival (P = 0.0383) in 108 patients with gastric cancer; C and D: According to the Kaplan–Meier analysis of data on gastric cancer from the 208853_s_at dataset, patients with CIP2A^high expression tumors had a significantly lower overall survival rate (P = 0.0040) (C) and progression-free survival rate (P < 0.0001) (D) than those with CIP2A^low expression tumors. CI: Confidence interval; HR: Hazard ratio.